<DOC>
	<DOC>NCT00889525</DOC>
	<brief_summary>This study was designed to check the efficacy of a new oral medical drug treatment, namely Cabergoline, for the treatment of Cushing Disease due to pituitary adenoma. Background: Cabergoline is a Dopamine 2 receptor agonist. Corticotroph adenoma has shown to have the D2 receptor in in vitro studies.</brief_summary>
	<brief_title>Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor</brief_title>
	<detailed_description />
	<mesh_term>Adenoma</mesh_term>
	<mesh_term>Pituitary Neoplasms</mesh_term>
	<mesh_term>Pituitary ACTH Hypersecretion</mesh_term>
	<mesh_term>ACTH-Secreting Pituitary Adenoma</mesh_term>
	<mesh_term>Cabergoline</mesh_term>
	<criteria>Patient with Cushing's disease uncured biochemically after pituitary surgery with adenoma on histopathology Patient's intolerance to drug or known sensitivity to ergot derivatives Pregnancy, lactation or female wishing to be pregnant Any serious medical illness Patient on any drugs known to have an interaction with cabergoline including antihypertensives like reserpine and methyl dopa, neuroleptics, metoclopramide, etc</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Cabergoline</keyword>
</DOC>